Home  Top Stories  Sports  Entertainment  Health News  Business  Personal Finance 
Real Estate  Business Finance  Insurance  Consulting 
Tax News  Forum


 

Writers






 


Featured Articles







BUSINESS



 


 

 
Search:

 

 



Osteoporosis Patients may Benefit From New Drug - Two Injections of Denosumab per Year will Increase Bone Mass in Postmenopausal Women

February 22nd 2006

Osteoporosis Patients may Benefit From New Drug - Two Injections of Denosumab per Year will Increase Bone Mass in Postmenopausal Women

Osteoclasts

New research has found that an investigational therapy for bone loss, denosumab, demonstrated significant increases in bone mineral density (BMD) in postmenopausal women with osteoporosis.  A person’s BMD can be an indicator for fracture risk, according to a study published in the Feb. 23, 2006 issue of The New England Journal of Medicine.

Denosumab is a RANK Ligand inhibitor under development by Amgen.  Ligand is a protein that is the primary “mediator” of osteoclast formation, function and survival.  These osteoclasts are responsible for bone removal. 

This study is in the second stage and the researchers were able to demonstrate that “denosumab provides rapid and sustained responses of bone metabolism in patients with low BMD.”  Denosumad can be administered twice yearly and will increase total hip, spine, distal 1/3 radius and total body BMD similar to current therapy.

 

The subcutaneous injections of denosumab increased BMD at the lumbar spine from 3.0 to 6.7 percent after 12 months as compared with a decrease of 0.8 percent with placebo.  The researchers also saw an improvement in hip BMD from 1.9 to 3.6 percent in women who received denosumab compared with a decrease of 0.6 percent in the placebo group.

The drug also acted quickly.  According to the study “denosumab had a rapid onset of action, inhibiting the action of osteoclasts within 72 hours”.  Dr. Michael McClung, MD said “The ability to control bone metabolism and increase BMD so effectively with such a convenient dosing regimen shows a potential advantage of this therapeutic strategy over current therapies."  Dr. McClung is the principal investigator of the denosumab study and director of Oregon Osteoporosis Center at Providence Portland Medical Center in Portland, Oregon.

 

The adverse side effects were similar to those of the placebo and Fosamax.  Because the drug is injected under the skin, the patients would avoid the gastrointestinal upset which is a side effect of the currently prescribed osteoporosis medications known as bisphosphonates. 

 
Comment on this Article at our Forum

Submit your own Article

Diet and Fitness Special Topic

  RSS Feed to our Diet & Fitness News

  RSS Feed to our health News

  RSS Feed to all of our News

Add to Google Add to My AOL
Add to My Yahoo! Subscribe with Pluck RSS reader
Subscribe in NewsGator Online
Add this feed to Your C-Net

By Dan Wilson
Best Syndication Staff Writer

Books on Dieting

Keywords and misspellings: osterporosis osteorenew boans milk suplements osteoparosis  rinonant rinomabent wieght watchers


Google
 
Web BestSyndication.com

About   Contact   site map

Copyright 2005 Best Syndication                                            Last Updated Saturday, July 10, 2010 09:50 PM